328 related articles for article (PubMed ID: 30623616)
61. Prognostic factors for primary Sjögren's syndrome-associated interstitial lung diseases.
Kamiya Y; Fujisawa T; Kono M; Nakamura H; Yokomura K; Koshimizu N; Toyoshima M; Imokawa S; Sumikawa H; Johkoh T; Yasui H; Hozumi H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Suda T
Respir Med; 2019 Nov; 159():105811. PubMed ID: 31710871
[TBL] [Abstract][Full Text] [Related]
62. Secukinumab decreases serum Krebs von den Lungen 6 (KL-6) level in patients with psoriasis with elevated serum KL-6 level.
Chijiwa C; Takeoka S; Kamata M; Uchida H; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
Br J Dermatol; 2018 Dec; 179(6):1396-1397. PubMed ID: 29985537
[No Abstract] [Full Text] [Related]
63. Evaluation of changes in the serum levels of Krebs von den Lungen-6 and surfactant protein-D over time as important biomarkers in idiopathic fibrotic nonspecific interstitial pneumonia.
Yamakawa H; Hagiwara E; Ikeda S; Iwasawa T; Otoshi R; Tabata E; Okuda R; Sekine A; Baba T; Iso S; Okudela K; Takemura T; Ogura T
Respir Investig; 2019 Sep; 57(5):422-429. PubMed ID: 31003951
[TBL] [Abstract][Full Text] [Related]
64. Krebs von den Lungen-6 (KL-6) as a diagnostic marker for pulmonary fibrosis: A systematic review and meta-analysis.
Wang C; Wang Q; Liu T; Zhu J; Zhang B
Clin Biochem; 2023 Apr; 114():30-38. PubMed ID: 36706799
[TBL] [Abstract][Full Text] [Related]
65. Pneumocyte biomarkers KL-6 and surfactant protein D reflect the distinct findings of high-resolution computed tomography in nonspecific interstitial pneumonia.
Ichiyasu H; Ichikado K; Yamashita A; Iyonaga K; Sakamoto O; Suga M; Kohrogi H
Respiration; 2012; 83(3):190-7. PubMed ID: 21555868
[TBL] [Abstract][Full Text] [Related]
66. Biomarkers from bronchoalveolar lavage fluid in systemic sclerosis patients with interstitial lung disease relate to severity of lung fibrosis.
Hesselstrand R; Wildt M; Bozovic G; Andersson-Sjöland A; Andréasson K; Scheja A; Westergren-Thorsson G; Bjermer L; Wuttge DM
Respir Med; 2013 Jul; 107(7):1079-86. PubMed ID: 23660398
[TBL] [Abstract][Full Text] [Related]
67. Exploration and correlation analysis of changes in Krebs von den Lungen-6 levels in COVID-19 patients with different types in China.
Xue M; Zheng P; Bian X; Huang Z; Huang H; Zeng Y; Hu H; Liu X; Zhou L; Sun B; Wu JL; Zhong N
Biosci Trends; 2020 Sep; 14(4):290-296. PubMed ID: 32565512
[TBL] [Abstract][Full Text] [Related]
68. Identification of serum interleukin-13 and interleukin-13 receptor subunit expressions: Rheumatoid arthritis-associated interstitial lung disease.
Hussein MS; El-Barbary AM; Nada DW; Gaber RA; Elkolaly RM; Aboelhawa MA
Int J Rheum Dis; 2021 Apr; 24(4):591-598. PubMed ID: 33638296
[TBL] [Abstract][Full Text] [Related]
69. Krebs von den Lungen 6 (KL-6) as a marker for disease severity and persistent radiological abnormalities following COVID-19 infection at 12 weeks.
Arnold DT; Donald C; Lyon M; Hamilton FW; Morley AJ; Attwood M; Dipper A; Barratt SL
PLoS One; 2021; 16(4):e0249607. PubMed ID: 33914762
[TBL] [Abstract][Full Text] [Related]
70. [The expression and clinical role of KL-6 in serum and BALF of patients with different diffuse interstitial lung diseases].
Zhu C; Zhao YB; Kong LF; Li ZH; Kang J
Zhonghua Jie He He Hu Xi Za Zhi; 2016 Feb; 39(2):93-7. PubMed ID: 26879611
[TBL] [Abstract][Full Text] [Related]
71. Surfactant protein D and KL-6 serum levels in systemic sclerosis: correlation with lung and systemic involvement.
Bonella F; Volpe A; Caramaschi P; Nava C; Ferrari P; Schenk K; Ohshimo S; Costabel U; Ferrari M
Sarcoidosis Vasc Diffuse Lung Dis; 2011 Jul; 28(1):27-33. PubMed ID: 21796888
[TBL] [Abstract][Full Text] [Related]
72. [Immunohistochemical Analysis of Krebs von den Lungen-6 (KL-6) Expression in Lung Tissue in Primary Lung Cancer Patients with High Serum KL-6 Levels].
Yatsuyanagi E; Sato K; Sato K
Kyobu Geka; 2015 Sep; 68(10):815-9. PubMed ID: 26329623
[TBL] [Abstract][Full Text] [Related]
73. Forensic application of three interstitial pneumonia markers: search for new pneumonia markers in dead bodies.
Okaba K; Inokuchi G; Horioka K; Iwase H; Inoue H; Motomura A; Ishii N; Moue C; Shiomi T; Yajima D
Int J Legal Med; 2024 Jul; 138(4):1583-1592. PubMed ID: 38379061
[TBL] [Abstract][Full Text] [Related]
74. Usefulness of monitoring the circulating Krebs von den Lungen-6 levels to predict the clinical outcome of patients with advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Ishikawa N; Hattori N; Yokoyama A; Tanaka S; Nishino R; Yoshioka K; Ohshimo S; Fujitaka K; Ohnishi H; Hamada H; Arihiro K; Kohno N
Int J Cancer; 2008 Jun; 122(11):2612-20. PubMed ID: 18324627
[TBL] [Abstract][Full Text] [Related]
75. CA 15-3 as an alternative marker for KL-6 in fibrotic lung diseases.
Kruit A; Gerritsen WB; Pot N; Grutters JC; van den Bosch JM; Ruven HJ
Sarcoidosis Vasc Diffuse Lung Dis; 2010 Jul; 27(2):138-46. PubMed ID: 21319596
[TBL] [Abstract][Full Text] [Related]
76. Beneficial impact of weight loss on respiratory function in interstitial lung disease patients with obesity.
Sekine A; Wasamoto S; Hagiwara E; Yamakawa H; Ikeda S; Okabayashi H; Oda T; Okuda R; Kitamura H; Baba T; Komatsu S; Ogura T
Respir Investig; 2021 Mar; 59(2):247-251. PubMed ID: 33189601
[TBL] [Abstract][Full Text] [Related]
77. KL-6 as an Immunological Biomarker Predicts the Severity, Progression, Acute Exacerbation, and Poor Outcomes of Interstitial Lung Disease: A Systematic Review and Meta-Analysis.
Zhang T; Shen P; Duan C; Gao L
Front Immunol; 2021; 12():745233. PubMed ID: 34956179
[TBL] [Abstract][Full Text] [Related]
78. Serum YKL-40 and Serum Krebs von den Lungen-6 as Potential Predictive Biomarkers for Rheumatoid Arthritis-Associated Interstitial Lung Disease.
Liang B; Zhang Y; Ke D; Yan R; Jiang MN; Li L; Zhang LX; Zhao XG; Yuan GP; Xu B; Liu XM
Immunol Invest; 2024 Jun; ():1-12. PubMed ID: 38900045
[TBL] [Abstract][Full Text] [Related]
79. Interstitial pulmonary disorders in indium-processing workers.
Chonan T; Taguchi O; Omae K
Eur Respir J; 2007 Feb; 29(2):317-24. PubMed ID: 17050566
[TBL] [Abstract][Full Text] [Related]
80. Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato/polymyositis.
Kumánovics G; Minier T; Radics J; Pálinkás L; Berki T; Czirják L
Clin Exp Rheumatol; 2008; 26(3):414-20. PubMed ID: 18578962
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
